



IRONSHORE

PHARMACEUTICALS & DEVELOPMENT, INC.

www.ironshorepharma.com

For Immediate Release:

IRONSHORE PHARMACEUTICALS TO PRESENT DATA AT SCIENTIFIC MEETINGS

- **Company also participating in a symposium about early morning functioning in ADHD**

George Town, Grand Cayman, October 21, 2016—Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc., today announced that it will be presenting clinical data and market research findings at the upcoming annual meetings of the American Academy of Pediatrics (“AAP”), being held in San Francisco, CA, October 21-25, 2016, and of the American Academy of Child and Adolescent Psychiatry (“AACAP”), being held in New York, NY, October 24-29, 2016.

“We look forward to more meaningful engagement with medical practitioners as we start to share data from our pivotal trials and continue the important dialogue regarding unmet needs in ADHD”, said David Lickrish, Ironshore’s Chief Executive Officer. “Ironshore has committed itself to the highest standards of scientific exchange and responsible conduct in dealing with healthcare providers and patients. Ironshore invites all physicians attending the AAP and AACAP conferences to visit with us to learn more about the important work we are doing.”

In addition to the presentation of several posters and abstracts, Ironshore’s Chief Medical Officer, Dr. Randy Sallee, will be a participant in a symposium at the AACAP meeting in New York. Details of the symposium are as follows:

Friday, October 28, 2016, 8:30 AM-11:30 AM

Early-Morning Functioning in Attention-Deficit/Hyperactivity Disorder: Impact, Measurement, and Treatment Considerations

Specific information about the data contained in the posters, abstracts and symposium is embargoed until the start of the meetings.

About Ironshore Pharmaceuticals & Development, Inc.

Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., is a specialty pharmaceutical company that is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products. Highland Therapeutics Inc. is a client of MaRS Discovery District's Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.

For further information, please contact:

Nelson F. Isabel, Chief Financial Officer
(647) 260-7875

Forward-Looking Statements

This press release contains forward-looking information, which reflects Ironshore's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Ironshore's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Ironshore assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.